Bora Pharmaceuticals CoTPE:6472 +1.74%87 EBITDA Margin % is 24.66% as of Dec. 2025, which is 23% below its 10-year median of 32.08. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 953 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 91.4% on this metric.
Bora Pharmaceuticals Co (TPE:6472) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bora Pharmaceuticals Co EBITDA Margin % Related Terms
Bora Pharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bora Pharmaceuticals Co (TPE:6472) has a EBITDA Margin % of 24.66% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bora Pharmaceuticals Co and its competitors. This is 23% below median its historical median of 32.08. Over the past decade, Bora Pharmaceuticals Co's EBITDA Margin % has ranged from 11.67 to 44.56. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #82 out of 953 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Bora Pharmaceuticals Co's EBITDA Margin % too high?
Bora Pharmaceuticals Co's current EBITDA Margin % of 24.66% is 23% below median its 10-year median of 32.08. Over the past 10 years, this metric has ranged from a low of 11.67 to a high of 44.56. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Bora Pharmaceuticals Co's value of 24.66% is 97.4% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #82 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #82 out of 953 companies for EBITDA Margin %. This places Bora Pharmaceuticals Co in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. Bora Pharmaceuticals Co's value of 24.66% is 97.4% above this benchmark. Historically, Bora Pharmaceuticals Co's own EBITDA Margin % has ranged from 11.67 to 44.56 over the past decade. While the company's 10-year median is 32.08 vs. the industry median of 12.49, Bora Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current EBITDA Margin % of 24.66% is 97.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current EBITDA Margin % is 24.66%, which is 23% below median its own 10-year median of 32.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current EBITDA Margin % is 24.66%, which is 23% below median its 10-year median of 32.08 and 97.4% above the Drug Manufacturers industry median of 12.49. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current EBITDA Margin % is 24.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
EBITDA Margin %: 24.66% (23% below median its 10-year median of 32.08)
GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
Industry Position: 97.4% above the Drug Manufacturers median (#82 of 953)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
